4-[1-(3-cyclohexyl-propionyl)-piperidin-4-yl]-1-oxazol-2-yl-butan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[1-(3-cyclohexyl-propionyl)-piperidin-4-yl]-1-oxazol-2-yl-butan-1-one
• 英文别名: 4-[1-(3-Cyclohexylpropanoyl)piperidin-4-yl]-1-(1,3-oxazol-2-yl)butan-1-one
• 化学式: C₂₁H₃₂N₂O₃
• 分子量: 360.497
• InChiKey: OFYUHKXWTJTAPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  63.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(2-Oxazolyl)-4-(4-piperidinyl)-1-butanone 、 3-环己基丙酰氯 以 二氯甲烷 为溶剂， 生成 4-[1-(3-cyclohexyl-propionyl)-piperidin-4-yl]-1-oxazol-2-yl-butan-1-one
  参考文献：
  名称：

  Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH)

  摘要：

  Efforts to improve the properties of the well studied ketooxazole FAAH inhibitor OL-135 resulted in the discovery of a novel propylpiperidine series of FAAH inhibitors that has a modular design and superior properties to OL-135. The efficacy of one of these compounds was demonstrated in a rat spinal nerve ligation model of neuropathic pain in rats. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.091

文献信息

• 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
  申请人：Apodaca Richard

  公开号：US20090111778A1

  公开（公告）日：2009-04-30

  Certain 2-keto-oxazole compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

  本文描述了某些2-酮噁唑类化合物，可用作FAAH抑制剂。这些化合物可以用于药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态，紊乱和情况的方法。因此，这些化合物可以用于治疗焦虑、疼痛、炎症、睡眠障碍、饮食障碍或运动障碍（如多发性硬化症）。
• [EN] 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] 2-CETO-OXAZOLES EN TANT QUE MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2007061862A2

  公开（公告）日：2007-05-31

  [EN] Certain 2-keto-oxazole compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
  [FR] La présente invention concerne certains composés de 2-céto-oxazole, qui sont utiles en tant qu'inhibiteurs de FAAH. De tels composés peuvent être utilisés dans des compositions pharmaceutiques et des procédés pour le traitement de maladies, de troubles et de pathologies véhiculés par l'activité amide d'acide gras hydrolase (FAAH). Par conséquent, les composés peuvent être administrés pour traiter, par exemple, l'anxiété, la douleur, l'inflammation, les troubles du sommeil, les troubles du comportement alimentaire, ou les troubles moteurs (tels que la sclérose en plaques).
• Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH)
  作者：Amy Timmons、Mark Seierstad、Rich Apodaca、Matt Epperson、Dan Pippel、Sean Brown、Leon Chang、Brian Scott、Michael Webb、Sandra R. Chaplan、J. Guy Breitenbucher

  DOI：10.1016/j.bmcl.2008.01.091

  日期：2008.3

  Efforts to improve the properties of the well studied ketooxazole FAAH inhibitor OL-135 resulted in the discovery of a novel propylpiperidine series of FAAH inhibitors that has a modular design and superior properties to OL-135. The efficacy of one of these compounds was demonstrated in a rat spinal nerve ligation model of neuropathic pain in rats. (c) 2008 Elsevier Ltd. All rights reserved.